Current Report Filing (8-k)
October 01 2021 - 5:29PM
Edgar (US Regulatory)
0001661053
false
12-31
0001661053
2021-09-29
2021-09-29
0001661053
HIJI:CommonStockParValue0.00001PerShareMember
2021-09-29
2021-09-29
0001661053
HIJI:WarrantToPurchaseCommonStockMember
2021-09-29
2021-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 29, 2021
enVVeno
Medical Corporation
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38325
|
|
33-0936180
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
70
Doppler
Irvine,
California 92618
(Address
of principal executive offices) (Zip Code)
(949)
261-2900
(Registrant’s
telephone number, including area code)
Hancock
Jaffe Laboratories Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.00001 per share
|
|
NVNO
|
|
The
NASDAQ Stock Market LLC
|
Warrant
to Purchase Common Stock
|
|
NVNOW
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
October 1, 2021, Hancock Jaffe Laboratories, Inc. (the “Company”) changed its name to “enVVeno Medical Corporation”
(the “Name Change”). The Name Change, which was effective as of 12:01 a.m. Eastern time on October 1, 2021 was accomplished
pursuant to a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fifth Amended and Restated
Certificate of Incorporation, as amended, filed with the Secretary of State of Delaware on September 29, 2021. The Company’s common
stock and the Company’s class of listed warrants continue to trade on the Nasdaq Capital Market under enVVeno Medical Corporation
and the new symbols are “NVNO” and “NVNOW”, respectively. A copy of the Certificate of Amendment is attached
as Exhibit 3.1 hereto and incorporated by reference herein.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
Exhibit
|
|
Description
|
|
|
|
3.1
|
|
Certificate of Amendment
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
enVVeno
Medical Corporation
|
|
|
Dated:
October 1, 2021
|
/s/
Robert A. Berman
|
|
Robert
A. Berman
|
|
Chief
Executive Officer
|
Hancock Jaffe Laboratories (NASDAQ:HJLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hancock Jaffe Laboratories (NASDAQ:HJLI)
Historical Stock Chart
From Sep 2023 to Sep 2024